Lynkeus biotech gmbh moneyhouse5/28/2023 Other observations include these: European biotechs have been good value for investorsīy 2018, the average size of biotech M&A deals in Europe had grown to $165 million-20 percent per annum growth since 2012, although deal prices were still only 58 percent of the US level ($284 million) in 2018. Our analysis showed that investment in European biotechs is increasing but that in late-stage financing, Europe lags behind the United States by a large (and still growing) margin. What financing is needed to encourage growth? In addition, a third of our experts think European biotechs lack a sufficiently entrepreneurial mind-set. Talent with experience in rare diseases and oncology is also thought to be in short supply. Companies often struggle to attract and retain talented staff who have experience in biotech and in business development. The talent base for research is strong however for drug development, it is smaller but growing. Would you like to learn more about our Life Sciences Practice? Top innovation and talentīiotech experts score Europe highly on its overall level of innovation and quality of R&D talent-just a fraction behind the United States and well ahead of China. Clearly, Europe has some way to go to catch up with the United States in patenting commercially relevant innovations and turning science into drugs. Late innovation (based on drug approvals and innovative candidates) is much lower, at 0.41. If we assess Europe’s performance against that of the United States and index the latter at 1.00, early innovation (measured by publications and patents) stands at 0.73 in Europe. Europe also shows great promise in emerging treatment areas: 32 percent of all European projects in Phase III or registration for products are based on technologies such as antisense, viral vectors, and siRNA. However, Europe’s share of new drugs could grow if its biotechs are able to attract more investment they currently receive only 20 percent of the funding their US counterparts do. Vaccines continue to be an area of focus in Europe total local funding is approximately 15 percent of the overall total.įurther down the innovation chain, European companies were responsible for originating 13 percent of the new drugs produced by biotechs and approved by the US Food and Drug Administration in 20, while US biotechs were responsible for 78 percent. In comparison, the United States focuses more on advanced-therapy medicinal products (about 20 percent of all biotech companies and all funding) than Europe does. These together represent half of the biotech companies in Europe (Exhibit 1). The three largest focus on providing services, on immunotherapies, and on brain and neuronal therapies. Through this exercise, we found that European biotechs can be grouped into eight clusters. (Also see our special report on the biotech market in Benelux, Scaling innovation: How Benelux could become Europe’s leading biotech hub.) This cluster map also shined light on the industry’s possible future directions. ![]() To see through the complexity, we grouped approximately 1,000 European biotech companies into clusters by country, modality, and therapeutic area so as to map biotech hot spots and trace how trends in the region are shifting over time. Hot spots in a fragmented landscapeĮurope has a complex biotech landscape: hundreds of companies, multiple paths to innovation and financing, and marked differences among countries. ![]() Our research indicated that three factors make Europe’s biotech market attractive to investors: strong hot spots across geographies, modalities, and therapeutic areas powerhouse research and industry expertise to support basic science and innovation and an abundance of high-caliber talent. This article shares highlights and reflections from our recent report on Europe’s biotech industry, Biotech in Europe: Scaling innovation, which focused on these three questions: What makes European biotech attractive, what financing does it need to fuel growth, and what should biotech leaders and investors do to succeed? What makes European biotech attractive? However, European companies have an opportunity to play an even stronger role in the growth of an important and dynamic industry. Europe’s role in this industry continues to grow, and the region leads in many ways. Yet more scientific and technological breakthroughs are on the horizon. CAR-T 2 Chimeric antigen receptor T cells.-into powerful new therapeutic tools. Biotech is entering its next S-curve of growth as companies work to transform an array of innovations-gene therapies, stem-cell treatments, antisense DNA, siRNA, 1 Small interfering ribonucleic acid.
0 Comments
Leave a Reply. |